Please use this identifier to cite or link to this item:
Title: Starving (or Fattening) the Golden Goose?: Generic entry and the incentives for early-stage pharmaceutical innovation
Authors: Branstetter, Lee 
Chatterjee, Chirantan 
Higgins, Matthew John 
Keywords: Pharmaceutical innovation;Pharmaceutical industry;Pharmaceutical policy
Issue Date: 2015
Publisher: National Bureau of Economic Research (NBER)
Series/Report no.: NBER Working Paper No. W20532
Abstract: Over the last decade, generic penetration in the U.S. pharmaceutical market has increased substantially, providing significant gains in consumer surplus. What impact has this rise in generic penetration had on the rate and direction of early stage pharmaceutical innovation? We explore this question using novel data sources and an empirical framework that models the flow of early-stage pharmaceutical innovations as a function of generic penetration, scientific opportunity, firm innovative capability, and additional controls. While the aggregate level of early-stage drug development activity has increased, our estimates suggest a sizable, robust, negative relationship between generic penetration and earlystage pharmaceutical research activity within therapeutic markets. A 10% increase in generic penetration is associated with a 7.9% decline in all early-stage innovations in the same therapeutic market. When we restrict our sample to first-in-class pharmaceutical innovations, we find that a 10% increase in generic penetration is associated with a 4.6% decline in early-stage innovations in the same market. Our estimated effects appear to vary across therapeutic classes in sensible ways, reflecting the differing degrees of substitution between generics and branded drugs in treating different diseases. Finally, we are able to document that with increasing generic penetration, firms in our sample are shifting their R&D activity to more biologic-based (large-molecule) products rather than chemical-based (smallmolecule) products. We conclude by discussing the potential implications of our results for long-run welfare, policy, and innovation.
Description: NBER Working Paper No. W20532
Appears in Collections:2010-2019

Files in This Item:
File SizeFormat 
Chatterjee_NBER_2015_WP_20532.pdf679.15 kBAdobe PDFView/Open
Show full item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.